The Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central Obesity

Syahidatul Wafa, Dicky Levenus Tahapary, Evy Yunihastuti, Heri Wibowo, Cleopas Martin Rumende, Kuntjoro Harimurti, Ketut Suastika, Farid Kurniawan, Rona Kartika, Tika Pradnjaparamita, Dante Saksono Harbuwono

Abstract


Background: Central obesity increases the risk of developing poor outcomes of COVID-19. The pro-inflammatory state and antibody dysfunction are thought to contribute to poor outcomes; however, the evidence is unclear. Methods: This is a cohort study among COVID-19 patients with central obesity in Dr. Cipto Mangunkusumo National General Hospital Jakarta, Indonesia, during the early phase of the COVID-19 pandemic. Our study is a part of the COVID-19, Aging, and Cardiometabolic Risk Factors (CARAMEL) study. From the CARAMEL study, we selected adult non-ICU/HCU inpatient subjects with central obesity that met inclusion/exclusion criteria, collected clinical and anthropometric data, and measured inflammatory cytokines and IgG S-RBD SARS-CoV-2 antibody titers from a stored sample taken at day 2 of hospitalization. The poor clinical outcome of hospitalization was observed. We used the Mann-Whitney test to analyse non-normally distributed data, and T-test for normally-distributed data. The adjusted-relative risk of negative seroconversion antibody for poor outcomes was analysed using logistic regression. Results: 23 of 178 (12.9%) subjects developed poor clinical outcomes during hospitalization. Subjects with poor outcomes had a higher visceral fat area (14.5 vs. 11, p < 0.05), waist circumference and BMI. The level of CRP, pro-inflammatory cytokines (IL-6 and MCP-1) and anti-inflammatory cytokines (IL-1Ra, IL-4, and IL-10) were significantly higher in subjects with poor outcomes, alongside with the lower antibody titer in subjects with poor outcomes. Antibody seroconversion failure increased the risk of developing poor outcomes (aRR 2.696, 95% CI 1.024-7.101), after adjusting for age and sex. Conclusion: In COVID-19 patients with central obesity, we confirmed the association between higher pro- and anti-inflammatory parameters, and lower SARS-CoV-2 antibody with poor outcomes of COVID-19.

Keywords


inflammatory parameters; antibody response; COVID-19 severity; central obesity; poor outcome

References


Liu Y, Douglas PS, Lip GYH, et al. Relationship between obesity severity, metabolic status and cardiovascular disease in obese adults. Eur J Clin Invest. 2023;53(3):e13912.

Tadayon Najafabadi B, Rayner DG, et al. Obesity as an independent risk factor for COVID-19 severity and mortality. Cochrane Database Syst Rev. 2023;5(5):CD015201.

Re F, Oguntade AS, Bohrmann B, et al. Associations of general and central adiposity with hypertension and cardiovascular disease among South Asian populations: a systematic review and meta-analysis. BMJ Open. 2023;13(12):e074050.

Goh VHH, Hart WG. Excess fat in the abdomen but not general obesity is associated with poorer metabolic and cardiovascular health in premenopausal and postmenopausal Asian women. Maturitas. 2018;107:33-8.

Földi M, Farkas N, Kiss S, et al. Visceral adiposity elevates the risk of critical condition in COVID‐19: A systematic review and meta‐analysis. Obesity. 2021;29(3):521-8.

Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56(4):1010-3.

Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract. 2005;69(1):29-35.

Schäffler A. [Role of metaflammation as a systemic manifestation of metabolic diseases]. Inn Med (Heidelb). 2023;64(4):313-22.

Frasca D, Blomberg BB. Adipose Tissue Inflammation Induces B Cell Inflammation and Decreases B Cell Function in Aging. Fronti Immunol. 2017;8(1003).

Frasca D, Reidy L, Cray C, et al. Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS One. 2021;16(3):e0245424.

Ren L, Zhang L, Chang D, et al. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Commun Biol. 2020;3(1):1-7.

Zohar T, Loos C, Fischinger S, et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell. 2020;183(6):1508-19. e12.

Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: a systematic review. PloS one. 2020;15(12):e0244126.

Tahapary D. COVID-19, Aging, and Cardiometabolic Risk Factors Study (CARAMEL) 2018 [cited 2024 31 May]. Available from: https://clinicaltrials.gov/ct2/show/NCT04802044)

World Health Organization. Regional Office for the Western P. The Asia-Pacific perspective : redefining obesity and its treatment: Sydney : Health Communications Australia; 2000

Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites. Front Immunol. 2021;12:746151.

Wacharasint P, Boyd JH, Russell JA, Walley KR. One size does not fit all in severe infection: obesity alters outcome, susceptibility, treatment, and inflammatory response. Crit Care. 2013;17(3):R122.

Domingos IF, Pereira-Martins DA, Sobreira MJVC, et al. High levels of proinflammatory cytokines IL-6 and IL-8 are associated with a poor clinical outcome in sickle cell anemia. Ann Hematol. 2020;99(5):947-53.

Korakas E, Ikonomidis I, Kousathana F, et al. Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes. Am J Physiol Endocrinol Metab. 2020;319(1):E105-E9.

Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128-36.e4.

Shekhawat J, Gauba K, Gupta S, et al. Interleukin-6 perpetrator of the COVID-19 cytokine storm. Indian J Clin Biochem. 2021;36(4):440-50.

Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: Plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995;107(4):1062-73.

Sheu K, Luecke S, Hoffmann A. Stimulus-specificity in the responses of immune sentinel cells. Curr Opin Syst Biol. 2019;18:53-61.

Yeung YT, Aziz F, Guerrero-Castilla A, Arguelles S. Signaling pathways in inflammation and anti-inflammatory therapies. Curr Pharm Des. 2018;24(14):1449-84.

Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754.

Frasca D, Blomberg BB. The impact of obesity and metabolic syndrome on vaccination success. Interdiscip Top Gerontol Geriatr. 2020;43:86-97.

Singh S, Anshita D, Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101(Pt B):107598.

Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight. 2020;5(13).

Motwani MP, Newson J, Kwong S, et al. Prolonged immune alteration following resolution of acute inflammation in humans. PLOS ONE. 2017;12(10):e0186964.

Song J, Deng T. The adipocyte and adaptive immunity. Front Immunol. 2020;11.

Tahtinen S, Tong A-J, Himmels P, et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022;23(4):532-42.

Takita M, Yoshida T, Tsuchida T, et al. Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19. Sci Rep. 2022;12(1):9147.

Lynch KL, Whitman JD, Lacanienta NP, et al. Magnitude and kinetics of anti–severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity. Clin Infect Dis. 2021;72(2):301-8.


Full Text: PDF

Refbacks

  • There are currently no refbacks.